Serum cardiovascular risk factors in obstructive sleep apnea

Chest

Volumn 129, Issue 2, 2006, Pages 233-237

  Can, Murat ^a   Açikgöz, Şerefden ^a   Mungan, Görkem ^a   Bayraktaroǧlu, Taner ^a   Koçak, Erdem ^a   Güven, Berrak ^a   Demirtas, Selda ^b  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Homocysteine; Obstructive sleep apnea

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANALYSIS OF VARIANCE; APNEA HYPOPNEA INDEX; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RISK FACTOR; SLEEP APNEA SYNDROME;

EID: 33344460969     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.2.233     Document Type: Article

References (33)

1. Olson LG, King MT, Hensley MJ, et al. Community study of snoring and sleep-disordered breathing: prevalence. Am J Respir Crit Care Med 1995; 152:711-716
2. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing in middle-aged adults. N Engl J Med 1993; 328:1230-1233
3. Goodday RH. Nasal respiration, nasal airway resistance, and obstructive sleep apnea syndrome. Oral Maxillofac Surg Clin North Am 1997; 9:167-177
4. Peled N, Greenberg A, Pillar G, et al. Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. Am J Hypertens 1998; 11:1284-1289
5. He J, Kryger MH, Zorick FJ, et al. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest 1988; 94:9-14
6. Mazza A, Bossone E, Mazza F, et al. Homocysteine and cardiovascular risk. Monaldi Arch Chest Dis 2004; 62:29-33
7. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44:6-11
8. Morozova S, Suc-Royer I, Auwerx J. Cholesterol metabolism modulators in future drug therapy for atherosclerosis. Med Sci (Paris) 2004; 20:685-690
9. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6:381-387
10. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J 2004; 148(Suppl):S14-S18
11. Jonkers IJ, Smelt AH, van der Laarse A. Hypertriglyceridemia: associated risks and effect of drug treatment. Am J Cardiovasc Drugs 2001; 1:455-466
12. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255:188-205
13. Rifai N, Ma J, Sacks FM, et al. Apolipoprotein (a) size and lipoprotein (a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study. Clin Chem 2004; 50:1364-1371
14. ASDA Diagnostic Classification Steering Committee. The International Classification of Sleep Disorders: diagnostic and coding manual. 2nd ed. Lawrence, KS: Allen Press, 1997
15. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, DC: National Institute of Health, 1968
16. Graham IM, Daly EL, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277:1775-1781
17. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236
18. Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan Study. Stroke 2004; 35:2263-2269
19. Wuillemin WA, Solenthaler M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis. Vasa 1999; 28:151-155
20. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 2001; 120:900-908
21. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004; 111:683-689
22. Svatikova A, Wolk R, Magera MJ, et al. Plasma homocysteine in obstructive sleep apnea. Eur Heart J 2004; 25:1325-1329
23. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818
24. Dugovskaya L, Lavie L, et al. Activation of oxidative metabolism and CD64 and CD11c expression in peripheral blood monocytes and neutrophils in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2002; 165:934-939
25. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104:503-516
26. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462-466
27. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194-1197
28. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62:499-506
29. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima; role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20:2094-2099
30. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003; 70:665-671
31. Mendall MA, Patel P, Ballam L, Strachan D, et al. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312:1061-1065
32. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105:2462-2464
33. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107:1129